Paratek's top an­tibi­ot­ic fails to clear a key com­pet­i­tive hur­dle in head-to-head stud­ies

It’s rarely a good day when tri­al da­ta comes back and one of the on­ly things you can say about the re­sults is that they told you what not to do.

But when Paratek Phar­ma­ceu­ti­cals’ CEO looked over the top line re­sults from two stud­ies eval­u­at­ing their Nuzyra an­tibi­ot­ic as a treat­ment for uri­nary tract in­fec­tions, there was lit­tle else he could say. That and praise the tri­al de­sign.

Al­though Nuzyra showed com­pa­ra­ble rates of “clin­i­cal ben­e­fit” to ex­ist­ing an­tibi­otics, it had a less pow­er­ful ef­fect on the mi­cro­bi­o­log­i­cal re­sponse – a key in­di­ca­tor of whether an in­fec­tion will re­turn. And that’s where an­a­lysts point­ed to a cru­cial miss.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER